The complete blood count (CBC) device is often used to screen for diseases as part of a medical assessment. It is useful in measuring the amounts of platelets, red and white blood cells, along with the hemoglobin and hematocrit values. By modality CBCs can be portable and stationary. Portable complete blood count devices are used to detect disorders including blood infection, anemia, and leukemia along with normal routine checkup of glucose in diabetic patients. Stationary complete blood count devices are mostly used in hospitals, diagnostics laboratories, and other large facilities to conduct multiple blood tests at a time.
The global complete blood count device market is estimated to be valued at US$ 3,642.9 million in 2021, and is expected to exhibit a CAGR of 8.3% over the forecast period (2021-2028).
Figure 1. Global Complete Blood Count Device Market Share (%), By Region, 2021
The increasing incidence of blood infection is expected to drive the growth of the global complete blood count device market over the forecast period.
For instance, according to the report published by World Health Organization in September 2020, sepsis kills 11 million people each year, globally. Moreover, sepsis occurs when chemicals released in the bloodstream to fight an infection trigger inflammation throughout the body. Thus, increasing incidence of severe blood infection is expected to increase the demand for white blood cell count (WBC or leukocyte count) test.
Moreover, according to the article published in the Journal of American Society for Nutrition, in May 2020, anemia prevalence was 22.8% globally, in 2019.
|Base Year:||2020||Market Size in 2021:||US$ 3,642.9 Mn|
|Historical Data for:||2017 to 2020||Forecast Period:||2022 to 2028|
|Forecast Period 2021 to 2028 CAGR:||8.3%||2028 Value Projection:||US$ 6,361.2 Mn|
Abbott Laboratories, bioMérieux SA, Danaher Corporation, Siemens Healthineers, Bio-Rad Laboratories, Inc., PerkinElmer, Inc., Sysmex Asia Pacific Pte Ltd, Becton, Dickinson and Company, Sight Diagnostics, Horiba, and Nihon Kohden Corporation
|Restraints & Challenges:||
Figure 2. Global Complete Blood Count Device Market Share (%) Analysis, By Product Type, 2021
The increasing product launches by key players operating in the market is expected to drive the market growth over the forecast period.
For instance, in February 2021, Beckman Coulter, a medical devices company, launched DxH 560 AL, a tabletop hematology analyzer designed to reduce the time and resource constraints faced by small to mid-sized diagnostic laboratories. Moreover, the DxH 560 AL delivers results in 60 seconds or less. It can be used with difficult-to-draw patients (infants, oncology, and elderly) because it only needs a 17 μL sample less than a drop of blood.
Global Complete Blood Count Device Market – Impact of Coronavirus (COVID-19) Pandemic
During this COVID-19 pandemic, pharmaceutical business, clinical tool companies and likewise biotechnology firms are facing difficulties that are occurring from the interruption in supply chains and the demand to transform service processes. One of the biggest challenges is supplying the raw materials required to manufacture the CBC devices due to irregularities in the transportation system.
Additionally, due to the increasing number of patients suffering from COVID-19 and other life-threatening illnesses, product distributors are seeing erratic demand for products from retailers. COVID-19 has impacted positively on the complete blood count device market as demand for CBC devices has increased. The complete blood count (CBC), which examines the quantity of red and white blood cells as well as other blood components, is a standard test used by clinicians to monitor patients. The CBC test is not used to diagnose COVID-19, but it is one of the tests used to examine the health of a patient who has been infected. For instance, in March 2020, Sight diagnostics, a blood diagnostics company, announced that Israel’s flagship government-run hospital Sheba Tel Hashomer was using Sight diagnostic’s OLO to conduct CBC tests to monitor and treat its COVID-19 patients.
Global Complete Blood Count Device Market - Restraint
High cost of CBC test & device are the factors that are expected to hinder growth of the global complete blood count device market over the forecast period. The cost of a CBC test can range anywhere between US$ 100 to over US$ 1,000 with or without insurance. The price depends on the type of test, location, and the type of insurance coverage.
Major players operating in the global complete blood count device market include Abbott Laboratories, bioMérieux SA, Danaher Corporation, Siemens Healthineers, Bio-Rad Laboratories, Inc., PerkinElmer, Inc., Sysmex Asia Pacific Pte Ltd, Becton, Dickinson and Company, Sight Diagnostics, Horiba, and Nihon Kohden Corporation.
A complete blood count (CBC), sometimes known as a full blood count (FBC), is a series of medical laboratory tests that give information regarding a person's blood cells. The CBC measures the number of white blood cells, red blood cells, and platelets, as well as hemoglobin concentration and hematocrit. The CBC is done with standard laboratory equipment or an automated hematological analyzer, which counts cells and records their size and structure. Three varieties of CBC devices exist: 3-part analyzer, 5-part analyzer, and 6-part analyzer.
The 3-part differential analyzer measures the volume of white blood cells electrically and classifies the cells based on their size, into three groups which include a small white blood cell group (lymphocytes), a medium-sized white blood cell group (monocytes, eosinophils, and basophils), and a large white blood cell group (neutrophils). A 5-part analyzer is a differential hematology instrument that uses the principle of flow cytometry to differentiate white blood cells (WBC) into their five major substitutes which include neutrophils, lymphocytes, monocytes, eosinophils, and basophils. 6-part analyzers are based on various technologies such as flow cytometry, light scattering, absorbance, electrical impedance, volume cytochemistry-based flow-cytometry, and other novel technologies.
Increasing approval of products launched by key players is expected to drive the growth of the global complete blood count device market in the forecast period. For instance, in January 2018, Abbott Laboratories announced that it had received CE Mark for its Alinity h-series integrated system for hematology testing. Moreover, the system offers high-throughput CBC analysis along with automated slide making and staining. It can perform 125 CBC per m2. It also integrates the Alinity hq with the Alinity hs slide maker and stainer module.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.